University of Groningen
Use of real-world evidence in pharmacoeconomic analysis
Huang, Yunyu
DOI:
10.33612/diss.95669767
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Huang, Y. (2019). Use of real-world evidence in pharmacoeconomic analysis: illustrations in The
Netherlands and China. University of Groningen. https://doi.org/10.33612/diss.95669767
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Use of Real-World Evidence in
Pharmacoeconomic Analysis
Illustrations for The Netherlands and China
Yunyu Huang
Use of Real-World Evidence in Pharmacoeconomic Analysis: Illustrations for The Netherlands and China
PhD dissertation, University of Groningen, University Medical Center Groningen, the Netherlands
The work presented in this thesis results from a joint Doctorate between the University of Groningen, University Medical Center Groningen, and Fudan University (Shanghai, China).
Financial support for the publication of this thesis was partially provided by the University of Groningen, University Medical Center Groningen, and Research Institute SHARE (Science in Healthy Ageing & healthcaRE).
ISBN: 978-94-034-1870-4 (printed version) 978-94-034-1869-8 (digital version)
Cover design and layout: Eduard Boxem | www.persoonlijkproefschrift.nl Printing: Ridderprint BV | www.ridderprint.nl
© 2019, Yunyu Huang, Groningen, the Netherlands
All rights reserved. No parts of this thesis may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system, without permission of the author.
Use of Real-World Evidence in
Pharmacoeconomic Analysis
Illustrations for The Netherlands and China
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. C. Wijmenga
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Monday 16 September 2019 at 11:00 hours
by
Yunyu Huang
born on 29 August 1985 in Shanghai, China
Supervisors Prof. F.M. Haaijer-Ruskamp Prof. M.J. Postma Co-supervisor Dr. P. Vemer Assessment committee Prof. K. Taxis Prof. S.M.A.A. Evers Prof. H.V. Hogerzeil
Paranymphs
Dr. J.F.M. van Boven Dr. H. Wang
TABLE OF CONTENTS
Chapter 1 Introduction 9
Chapter 2 Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review
21
Chapter 3 Using primary care electronic health record data for comparative effectiveness research: experience of data quality assessment and preprocessing in The Netherlands
61
Chapter 4 Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes
81
Chapter 5 Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data
105
Chapter 6 Cost-effectiveness and budget impact analysis of improvement of medication utilization in patients with type 2 diabetes and nephropathy from a healthcare payer perspective in China
127
Chapter 7 General discussion and future perspectives 155
Summary 168
Appendices
Nederlandse samenvatting 172
Acknowledgments 176
